Chugai Pharmaceutical (OTCMKTS:CHGCY) Releases Earnings Results

Chugai Pharmaceutical (OTCMKTS:CHGCY) released its earnings results on Thursday. The company reported $0.18 earnings per share for the quarter, Zacks reports. Chugai Pharmaceutical had a return on equity of 22.30% and a net margin of 33.85%.

Chugai Pharmaceutical Price Performance

CHGCY traded down $0.30 during midday trading on Thursday, reaching $20.33. 89,914 shares of the company’s stock traded hands, compared to its average volume of 189,677. The stock has a market capitalization of $66.91 billion, a price-to-earnings ratio of 26.06 and a beta of 0.81. The firm has a fifty day moving average of $21.62 and a two-hundred day moving average of $22.43. Chugai Pharmaceutical has a 52 week low of $14.52 and a 52 week high of $26.00.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.